CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 370 enrolled
Drug / intervention
5 mg ASB17061 +3 moredrug
Likely dose
5 mg ASB17061from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01756898
NCT01756898Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Daiichi Sankyo·interventional·Posted Dec 28, 2012·Updated Feb 16, 2021

In Brief

A Phase 2 clinical trial evaluating 5 mg ASB17061, Placebo, and 2 other interventions for Atopic Dermatitis. Completed, enrolled 370 participants across 40 sites.

Detailed Summary

The purpose of this research study is to gather scientific information about the effectiveness of the study drug, ASB17061 capsules, when compared to placebo in adult subjects with atopic dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 28, 2012
Enrollment StartNov 28, 2012
Primary CompletionJan 14, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.5 years ago

Interventions

5 mg ASB17061drug

Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.

Placebodrug

Oral administration of placebo taken once daily for 28 consecutive days.

10 mg ASB17061drug

Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.

20 mg ASB17061drug

Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.